with heart failure (5, 6). Therefore, early detection and prevention of such cardiac dysfunction is an important goal in the management of hypertensive patients. In a study by Phillips et al. (7), however diastolic abnormalities of ventricular function persisted despite effective control of blood pressure in treated hypertensive patients, and these abnormalities were independent of LV hypertrophy, suggesting that some factor other than blood pressure or cardiac hypertrophy may affect diastolic function in treated hypertension.
Introduction
Left ventricular (LV) hypertrophy and LV diastolic dysfunction, which are common cardiac consequences of hypertension, are known to be independent risk factors for cardiovascular mortality (1) (2) (3) . A previous study reported that diastolic dysfunction should be considered in patients presenting with heart failure symptoms but with normal systolic function, particularly in hypertensive patients with LV hypertrophy (4) . Indeed, diastolic dysfunction precedes LV systolic impairment and alone accounts for about 30-40% of patients LV diastolic properties (8) . Moreover, previous studies have reported that the diastolic impairment of LV observed in diabetic patients was essentially irreversible despite the long periods of improvement in glycemic control (9, 10) . And the Framingham Study revealed that not only diabetes but also impaired glucose tolerance is a significant risk factor for congestive heart failure (11, 12) . These findings suggest that it is important to watch for early abnormalities in glucose metabolism in addition to blood pressure control in managing hypertensive patients, especially to preserve a good diastolic performance of their hearts. However, the influence of minor degrees of hyperglycemia on cardiac diastolic function has not been sufficiently elucidated. Thus, we conducted the present study to investigate whether a slight elevation of plasma glucose levels affects LV structure and function, particularly LV diastolic function, in nondiabetic patients with treated essential hypertension.
Methods

Patients
A total of 193 patients with essential hypertension (96 males and 97 females; mean age, 60 13 years) were enrolled in our retrospective study. Standardized measurements of seated brachial blood pressure, anthropometric examinations, and blood samplings to determine fasting plasma glucose (FPG) and HbA1c levels were performed. Blood samples were obtained in the morning after an overnight (10 -12 h) fast. Patients with secondary hypertension, ischemic heart disease including myocardial infarction, valvular heart disease, atrial fibrillation, congestive heart failure, renal failure (serum creatinine 01.5 mg/dl), or unsatisfactory B-mode and Doppler echocardiograms were excluded from this study. Individuals with diabetes mellitus, which was diagnosed using American Diabetes Association criteria (13) , such as a FPG of 0126 mg/dl and/or a plasma glucose level at 2 h after 75 g oral glucose load of 0200 mg/dl, or participants receiving hypoglycemic medication were also excluded from the study. Hypertension was defined as a systolic blood pressure of 0140 mmHg and/or a diastolic blood pressure of 090 mmHg by repeated measurements or when medication was taken for treatment of hypertension.
The clinical characteristics of all subjects are summarized in Table 1 . Among the 193 patients, 156 (81%) were receiving antihypertensive drugs, including combination therapy in some cases. One hundred and twenty-two patients (63%) were treated with calcium channel blockers, 60 (31%) with β-blockers, 56 (29%) with angiotensin converting enzyme (ACE) inhibitors, 24 (12%) with diuretics, and 19 (10%) with other classes of agents. Thirty-seven patients (19%) were treated with diet and/or exercise therapy (without antihypertensive medication). All subjects gave their informed consent to participate in the present study.
Echocardiographic Measurement
On the day or within a week of the blood sampling, comprehensive two-dimensional echocardiography was performed using a cardiac ultrasound unit (Sonos 5500; Hewlett Packard, Andover, USA) as previously described (14) . Echocardiographic parameters were measured by the consensus of two experienced investigators who were blinded to the metabolic data of the subjects. Measurements included interventricular septal thickness (IVSTd), posterior wall thickness (PWTd), LV diameter at end-diastole (LVDd), and LV diameter at end-systole (LVDs). Fractional shortening was calculated as (LVDd LVDs)/LVDd. LV relative wall thickness (RWT) was calculated as (IVSTd PWTd)/LVDd. LV mass was estimated using the formula validated by Devereux and Reichek (15) : LV mass (g) 1.04 {(IVSTd PWTd LVDd) 3 LVDd 3 } 13.6. LV mass was normalized for body surface area and expressed as LV mass index (LVMI).
To assess LV diastolic function, the diastolic filling of LV (LV inflow) was examined using Doppler echocardiography. The LV diastolic filling pattern was obtained with the sample volume at the tips of the mitral valve in the apical fourchamber view and recorded at the end-expiratory phase during quiet breathing (16) . The peak velocity of the early diastolic filling wave (E wave) and the peak velocity of atrial filling (A wave) were recorded and the A to E ratio (A/E) was calculated. The deceleration time was measured as the time between the top of the E wave and the point where the descending part of the E wave or its asymptote crossed the zero line. 
Statistical Analysis
Values are expressed as the mean SD. Relations between variables were assessed using univariate linear regression analyses and Pearson's correlation coefficient. Multiple regression analyses were also performed to identify possible determinants of LV diastolic function. An unpaired Student's t-test was used for comparison between the two groups. Values of p 0.05 were considered to indicate statistical significance.
Results
We examined the correlation between glucose levels and other parameters, including LV structure and function, in all subjects. FPG had a weak positive correlation with age, and HbA1c was significantly correlated with age and body mass index (Table 2 ). FPG and HbA1c showed no association with blood pressure, heart rate, LV wall thickness, LV dimension, indices of LV hypertrophy (RWT and LVMI), or LV systolic function (fractional shortening). On the other hand, the glucose levels had a significant relation to LV diastolic dysfunction; that is, FPG was positively correlated with the A/E ratio ( Fig. 1) and HbA1c was positively correlated with the A/E ratio and the deceleration time. The A/E ratio was also correlated with age (r 0.49, p 0.001), IVSTd (r 0.23, p 0.001), PWTd (r 0.19, p 0.009), RWT (r 0.24, p 0.001), and LVMI (r 0.18, p 0.01). Systolic and diastolic blood pressures were positively correlated with IVSTd, PWTd, and LVMI, but not with the A/E ratio (data not shown).
Next, subjects were divided by their FPG levels into two groups: a group in which FPG was 100 mg/dl (group 1, n 140) and one in which FPG was 0100 mg/dl (group 2, n 53). In the comparison of clinical characteristics, no intergroup differences were found in the percentage of treatment with any of the antihypertensive drugs, or indeed in any other variable other than FPG and HbA1c (Table 3) . LV structure, hypertrophy, and systolic function also did not differ between the two groups (Table 4) . With regard to LV diastolic function, however, A wave velocity and the A/E ratio were significantly higher in group 2 than in group 1.
To confirm whether the effect of glucose levels on LV diastolic function was independent of other factors, especially age and LV hypertrophy, we investigated possible predictive factors for the A/E ratio using a multiple regression analysis in all subjects. Only age (p 0.001) and FPG (p 0.002) were found to be independent determinants of the A/E ratio ( Table 5) .
Discussion
The present study has clearly demonstrated that FPG is one of the determinants of LV diastolic dysfunction in nondiabetic patients with treated essential hypertension, and that the influence of plasma glucose on diastolic function is independent of that exerted by LV hypertrophy. Therefore, our findings suggest that a mild elevation of plasma glucose (mildly impaired glucose metabolism) in these patients may deteriorate specifically LV diastolic function, even if antihypertensive treatments keep blood pressure elevation and progression of hypertrophy under control. The HbA1c level was not an independent determinant of the A/E ratio in the present study, despite the fact that HbA1c is thought to be superior to FPG as an indicator of glycemic control. The smaller variation of HbA1c in nondiabetic patients might partly account for this discrepancy, because almost all the subjects (92%) had normal levels of HbA1c in our study. Alternatively, since HbA1c and age were more closely correlated than FPG and age, the relation between HbA1c and the A/E ratio in the multiple regression analysis may have been drowned out by the age factor, which was the most powerful predictor for A/E.
Many studies have reported that diabetes mellitus and hypertension additively augment LV hypertrophy and diastolic dysfunction (8, 9, (17) (18) (19) (20) (21) . Two of these studies reported that diabetic hypertensives had greater LVMI and more abnormalities in LV relaxation (decrease in E/A and prolongation of the deceleration time) than did nondiabetic hypertensives (8, 9) . Although prolonged LV relaxation and increased LV mass are common findings in hypertensive subjects, these observations suggest that the combination of diabetes and hypertension induces more progressive LV hypertrophy and more deteriorative diastolic function than hypertension alone. Therefore, it is probable that the complication of diabetes simultaneously enhances both structural and functional changes of LV in hypertensive patients.
On the other hand, there are somewhat limited findings concerning cardiac changes in patients with minor abnormalities in glucose homeostasis (i.e., impaired FPG and impaired glucose tolerance). Celentano et al. (22) showed in a population-based sample that a decrease in the E/A ratio was observed not only in subjects with overt diabetes mellitus, but also in those with impaired glucose tolerance, and that this diastolic abnormality in patients with glucose intolerance was not accompanied with an increase in LVMI or RWT. As for the influence of abnormal glucose metabolism on cardiac diastolic function in nondiabetic and hypertensive subjects, Nagano et al. (23) and Jain et al. (24) revealed that plasma glucose levels were associated with indices of diastolic dysfunction but not with LVMI. However, the sample sizes in their studies were small. In the present study, we demonstrated using a larger population of hypertensive patients that a slight elevation of FPG exaggerated LV diastolic dysfunction but did not promote LV hypertrophy in treated hypertensive patients. Similar findings were reported by Mizushige et al. (25) in their recent in vivo study. Using a rat model of type 2 diabetes mellitus, they demonstrated that a mild metabolic abnormality produced the delayed relaxation of LV at the prediabetic stage before the development of LV hypertrophy. These observations, together with those of the present study, strongly suggest that minor degrees of hyperglycemia selectively provoke LV diastolic dysfunction, an early alteration of cardiac function in hypertensive patients, independent of cardiac hypertrophy. In contrast to these findings, however, some studies have reported that FPG levels did not directly correlate with the deterioration of LV diastolic function (26, 27) , and one study suggested that the diastolic dysfunction of LV in hypertensive patients with glucose intolerance might simply be due to exaggerated LV hypertrophy (26) . The exact reason for the discrepant findings among these studies is unclear, but it may be partly related to differences in the basal clinical parameters affecting cardiac structure or function such as age, body mass index, and blood pressure level among the study populations.
In the present study, mild abnormalities of glucose homeostasis affected only cardiac diastolic function, without an increase in LV mass. There are several possible explanations for the specificity of this effect. With regard to the pathogenetic mechanism, interstitial accumulation of advancedglycated end products, which include collagen, elastin, and other connective tissue proteins, may be responsible for alterations of the diastolic properties of the heart in persons with hyperglycemia (28, 29) . In fact, it has been confirmed that collagen deposition in the myocardial interstitium of type 2 diabetic rats is already increased at the prediabetic stage (25) . Furthermore, we observed that high-glucose conditions increased collagen synthesis by cardiac fibroblasts but did not affect hypertrophy of cardiac myocytes using cultured ventricular cells (unpublished observations). Since such interstitial fibrosis can increase diastolic stiffness, the increase in the extracellular matrix induced by hyperglycemia might deteriorate LV diastolic function independent of the effects of myocyte hypertrophy.
As another possible mechanism, we cannot rule out the involvement of hyperinsulinemia and insulin resistance on cardiac function in patients with hypertension and glucose intolerance, although we did not determine the plasma insulin concentration or insulin sensitivity in the present cohort. Many studies have reported that the existence of hyperinsulinemia or insulin resistance is related to LV diastolic dysfunction in nondiabetic hypertensives (27, (30) (31) (32) (33) (34) (35) . In addition, some of these studies reported that the relation between the two was independent of LVMI (31) (32) (33) . Studies on the association between insulin and LV mass in humans have yielded conflicting results (23, 27, 31, (33) (34) (35) (36) (37) (38) (39) (40) , but recent studies have demonstrated that neither plasma insulin concentration nor insulin sensitivity is an independent determinant of LVMI in nondiabetic subjects (38, 39) . Therefore, the findings in our study might have been at least partly caused by hyperinsulinemia linked to glucose intolerance and hypertension. However, some studies have reported that hyperinsulinemia itself was not associated with indices of LV diastolic function, such as the A/E ratio in nondiabetic hypertension (23, 24, 26, 27) . Liu et al. (8) also reported that abnormal LV relaxation in diabetic patients was related to FPG and HbA1c rather than insulin. Further investigations will be needed to clarify which factor among hyperglycemia, hyperinsulinemia, and insulin resistance has the greatest impact on cardiac diastolic function.
Our study demonstrated the specific influence of plasma glucose on diastolic properties of the heart in patients with chronically treated essential hypertension, but not in untreated patients. This result may indicate that LV diastolic dysfunction is promoted by a metabolic factor such as hyperglycemia, even if antihypertensive treatments suppress the elevation of blood pressure and the subsequent progression of cardiac hypertrophy. A recent study showed that a long period (4 years) of improvement in glycemic control in type 2 diabetes did not contribute to the reversal of impaired LV diastolic function despite the regression of LV hypertrophy, suggesting that abnormalities in diastolic function at the diabetic stage are largely irreversible (9) . Another study also reported that 2 years of intensive glycemic control failed to ameliorate LV diastolic function in type 2 diabetic patients (10) . On the basis of these findings and the present observations, not only a satisfactory blood pressure control but also a strict glycemic control at the early stage may be important to protect hypertensive patients from the deterioration of LV diastolic function.
There were some limitations in the present study. Although we assessed LV diastolic dysfunction primarily by means of the A/E ratio, it is important to note that LV diastolic filling patterns determined by Doppler echocardiographic measurements provide only an indirect estimate of LV diastolic function. Moreover, LV filling is influenced by a variety of factors, such as ventricular relaxation, myocardial stiffness, coronary blood flow, preload, afterload, atrial function, heart rate, and age. Despite these limitations and the indirect method of estimation, LV inflow velocity recordings are noninvasive and practical, and have clinical potential for assessing diastolic properties in patients with heart disease (16, 41, 42) . In addition, LV diastolic function as measured by Doppler echocardiographic filling variables is affected very early in hypertension and frequently precedes the development of overt LV hypertrophy (7, 43) .
The majority of patients in the present study had received antihypertensive drugs in our hospital. As another limitation of this study, therefore, we must consider the possibility that some types of antihypertensive agents may have affected the cardiac structure and function apart from their actions on blood pressure, or may have influenced the glucose tolerance. In fact, previous studies have reported that an ACE inhibitor was effective in improving both cardiac performance and glucose/insulin metabolism in hypertensive patients (34, 44) .
In conclusion, our observations suggest that FPG is a sen-sitive predictor for LV diastolic dysfunction in nondiabetic patients with treated essential hypertension, and that a slight increase in plasma glucose levels can induce LV diastolic dysfunction, independent of LV hypertrophy. Therefore, a mild impairment in glucose metabolism may specifically deteriorate cardiac diastolic function even in hypertensive patients under adequate blood pressure control.
